109 related articles for article (PubMed ID: 26201703)
1. A Bagged, Partially Linear, Tree-Based Regression Procedure for Prediction and Variable Selection.
Mbogning C; Perdry H; Broët P
Hum Hered; 2015; 79(3-4):182-93. PubMed ID: 26201703
[TBL] [Abstract][Full Text] [Related]
2. Bagging survival tree procedure for variable selection and prediction in the presence of nonsusceptible patients.
Mbogning C; Broët P
BMC Bioinformatics; 2016 Jun; 17(1):230. PubMed ID: 27266372
[TBL] [Abstract][Full Text] [Related]
3. Multi-omics facilitated variable selection in Cox-regression model for cancer prognosis prediction.
Liu C; Wang X; Genchev GZ; Lu H
Methods; 2017 Jul; 124():100-107. PubMed ID: 28627406
[TBL] [Abstract][Full Text] [Related]
4. Prognostic model for brain metastases from lung adenocarcinoma identified with epidermal growth factor receptor mutation status.
Li H; Wang W; Jia H; Lian J; Cao J; Zhang X; Song X; Jia S; Li Z; Cao X; Zhou W; Han S; Yang W; Xi Y; Lian S
Thorac Cancer; 2017 Sep; 8(5):436-442. PubMed ID: 28597503
[TBL] [Abstract][Full Text] [Related]
5. Lung adenocarcinoma: Assessment of epidermal growth factor receptor mutation status based on extended models of diffusion-weighted image.
Yuan M; Pu XH; Xu XQ; Zhang YD; Zhong Y; Li H; Wu JF; Yu TF
J Magn Reson Imaging; 2017 Jul; 46(1):281-289. PubMed ID: 28054731
[TBL] [Abstract][Full Text] [Related]
6. Random generalized linear model: a highly accurate and interpretable ensemble predictor.
Song L; Langfelder P; Horvath S
BMC Bioinformatics; 2013 Jan; 14():5. PubMed ID: 23323760
[TBL] [Abstract][Full Text] [Related]
7. Computed tomography and clinical features associated with epidermal growth factor receptor mutation status in stage I/II lung adenocarcinoma.
Zou J; Lv T; Zhu S; Lu Z; Shen Q; Xia L; Wu J; Song Y; Liu H
Thorac Cancer; 2017 May; 8(3):260-270. PubMed ID: 28383802
[TBL] [Abstract][Full Text] [Related]
8. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC
Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317
[TBL] [Abstract][Full Text] [Related]
9. Discriminant analysis when all variables are ordered.
Johnston B; Seshia SS
Stat Med; 1992 Jun; 11(8):1023-32. PubMed ID: 1496190
[TBL] [Abstract][Full Text] [Related]
10. SVM-RFE: selection and visualization of the most relevant features through non-linear kernels.
Sanz H; Valim C; Vegas E; Oller JM; Reverter F
BMC Bioinformatics; 2018 Nov; 19(1):432. PubMed ID: 30453885
[TBL] [Abstract][Full Text] [Related]
11. Part 1. Statistical Learning Methods for the Effects of Multiple Air Pollution Constituents.
Coull BA; Bobb JF; Wellenius GA; Kioumourtzoglou MA; Mittleman MA; Koutrakis P; Godleski JJ
Res Rep Health Eff Inst; 2015 Jun; (183 Pt 1-2):5-50. PubMed ID: 26333238
[TBL] [Abstract][Full Text] [Related]
12. Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.
Balko JM; Potti A; Saunders C; Stromberg A; Haura EB; Black EP
BMC Genomics; 2006 Nov; 7():289. PubMed ID: 17096850
[TBL] [Abstract][Full Text] [Related]
13. Partially linear monotone methods with automatic variable selection and monotonicity direction discovery.
Engebretsen S; Glad IK
Stat Med; 2020 Nov; 39(25):3549-3568. PubMed ID: 32851696
[TBL] [Abstract][Full Text] [Related]
14. Dual surrogate markers for rapid prediction of epidermal growth factor receptor mutation status in advanced adenocarcinoma of the lung: A novel approach in resource-limited setting.
Udupa KS; Rajendranath R; Sagar TG; Sundersingh S; Joseph T
Indian J Cancer; 2015; 52(3):266-8. PubMed ID: 26905105
[TBL] [Abstract][Full Text] [Related]
15. Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Cha YK; Lee HY; Ahn MJ; Choi YL; Lee JH; Park K; Lee KS
Clin Lung Cancer; 2015 May; 16(3):228-36. PubMed ID: 25499173
[TBL] [Abstract][Full Text] [Related]
16. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
[TBL] [Abstract][Full Text] [Related]
17. Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma.
Tsai TH; Wu SG; Chang YL; Wu CT; Tsai MF; Wei PF; Yang CH; Yu CJ; Yang PC; Shih JY
J Thorac Oncol; 2012 Jun; 7(6):993-1000. PubMed ID: 22525557
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide prediction using Bayesian additive regression trees.
Waldmann P
Genet Sel Evol; 2016 Jun; 48(1):42. PubMed ID: 27286957
[TBL] [Abstract][Full Text] [Related]
19. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
20. High-dimensional sparse vine copula regression with application to genomic prediction.
Sahin Ö; Czado C
Biometrics; 2024 Jan; 80(1):. PubMed ID: 38465987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
